🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesNNT for MACE prevention — need advice Page 2

NNT for MACE prevention — need advice

MounjBrad Fri, Feb 13, 2026 at 10:36 PM 13 replies 976 viewsPage 2 of 3
hank_denver
Member
278
1,234
Sep 2024
Denver, CO
Feb 14, 2026 at 10:04 AM#6
MounjBrad said:
SELECT is the trial that changed the framing of this class, because it was an outcome trial rather than a weight trial: about a 20% relative reduction…

Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my key markers:

Weight: consistent downtrend, -1.5 lbs/week average
Fasting glucose (finger stick): stable at 86 mg/dL
Blood pressure (home): 115/72 average
Resting heart rate: 66 bpm (down from 82)
Waist circumference: down 16 inches total

The resting heart rate improvement correlates with cardiovascular fitness gains. Everything is moving in the right direction.

Last edited: Feb 14, 2026 at 2:04 PM
39 17ingrid_STO, pete_nash, hank_denver and 36 others
Reply Quote Save Share Report
BrianDallas92
Member
312
1,456
Oct 2024
Dallas, TX
Feb 14, 2026 at 2:36 PM#7

A narrower follow-up, since the general answer is now clear:

Did your prescriber agree with that reading, and if not what was their objection?

40 18mona_PHX, andrew_nyc, Dr.EndoEP and 37 others
Reply Quote Save Share Report
pat_auckland
Member
345
1,567
Jun 2024
Auckland, NZ
Feb 14, 2026 at 7:08 PM#8
hank_denver said:
Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my…

Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history. Results were encouraging:

  • NT-proBNP: 52 pg/mL (normal, cardiac function preserved)
  • Lp(a): 52 nmol/L (genetic, unchanged — expected)
  • ApoB: dropped from 142 to 92 mg/dL (excellent response)
  • Coronary calcium score: 0 (unchanged from baseline — reassuring)

The ApoB reduction is particularly meaningful — it's considered the best single predictor of cardiovascular risk. GLP-1 therapy seems to improve this consistently.

Last edited: Feb 14, 2026 at 11:08 PM
41 19LarryQC_SD, wanda_boise, NurseAsh_DET and 38 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
MounjBrad
Member
278
890
Oct 2024
Kentucky
Feb 14, 2026 at 11:39 PM#9
hank_denver said:
Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my…

I'm 58 years old and want to share my perspective on cardiovascular risk as an older member of this community.

My doctor was initially hesitant because of my age, but the SELECT trial included patients up to 72 and showed consistent benefit across age groups. We started at the lowest dose with closer monitoring.

11 months later: down 48 lbs, off metoprolol, A1C from 7.6% to 5.3%. My cardiologist is thrilled. cardiovascular risk is absolutely relevant for older adults — don't let anyone tell you otherwise.

42 20pam_columbus, nick_SD_fit, ben_calgary and 39 others
Reply Quote Save Share Report
Dr.RheumBOS
Member
567
2,345
Apr 2024
Boston, MA
Feb 15, 2026 at 9:21 PM#10
pat_auckland said:
Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history.

6 month update on cardiovascular risk: down 62 lbs, off blood pressure meds, A1C normalized. Genuinely life-changing.

10 10Dr.PulmRoch, maya_sedona, stefan_berlin and 7 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register